OakChart

Biofrontera Inc

BFRIHealthcare·Drug Manufacturers - Specialty & Generic·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.9375+0.0095 (1.02%)
2026-11-11 23:23 CET
Market cap
13.78 USD m
Revenue, TTM
46.17 USD m
Net income, TTM
-6.37 USD m
Free cash flow, TTM
-7.93 USD m
EPS diluted, TTM
-0.59
P/E
-
Compare

Price

BFRI against its 20, 50 and 200-day averages
2050200missearnings
0.751.001.251.501.2M2.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BFRIclose 0.9420-day 0.8550-day 1.05200-day 1.030.9452w high

43.5% under the 52-week high of 1.66 on 8 Sep 2026. 52-week low 0.56 on 31 Dec 2025. Last 15 sessions, 21.8% high to low

Volume 0.22× normal · the line is the 50-bar volume average

Profile

BFRI
52-week range, 35% of the way up
0.551.66

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Employees92
IPOOct 29, 2021
Beta0.94
ATR, 14d0.07
Rel volume0.22
Short float1.48%
Insider own13.53%
Inst own26.24%

Snapshot

6 groups

Valuation

Index-
Market Cap13.92M
Enterprise Value16.75M
Income-6.37M
Sales46.17M
Book/sh0.42
Cash/sh0.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees92
IPOOct 29, 2021

Ratios

P/E-
Forward P/E2.18
PEG-
P/S0.30
P/B2.24
P/C2.98
P/FCF-
EV/EBITDA-
EV/Sales0.36
Quick Ratio1.08
Current Ratio1.18
Debt/Eq1.26
LT Debt/Eq1.18
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.59
EPS next Y0.43
EPS next Q-0.11
EPS this Y82.69%
EPS next Y338.89%
EPS next 5Y-
EPS past 3/5Y-19.60% 44.08%
Sales past 3/5Y13.30% 17.21%
EPS Y/Y TTM73.13%
Sales Y/Y TTM17.83%
EPS Q/Q91.80%
Sales Q/Q32.92%
EarningsNov 13 BMO
EPS/Sales Surpr.52.38% 26.35%

Ownership

Insider Own13.53%
Insider Trans0.00%
Inst Own26.24%
Inst Trans8.35%
ROA-28.80%
ROE-988.35%
ROIC-49.01%
Gross Margin89.47%
Oper. Margin-2.97%
Profit Margin-13.78%
SMA209.95%
SMA50-10.94%
SMA200-9.14%
Trades-

Technical

Shs Outstand14.21M
Shs Float12.84M
Short Float1.48%
Short Ratio0.39
Short Interest0.19M
52W High1.66 -43.52%
52W Low0.55 69.01%
Volatility9.01% 7.81%
ATR (14)0.07
RSI (14)52.24
Beta0.94
Rel Volume0.22
Avg Volume485.41K
Volume105,774

Performance

Perf Week3.73%
Perf Month5.08%
Perf Quarter-25.60%
Perf Half Y-2.32%
Perf YTD64.47%
Perf Year-9.86%
Perf 3Y-75.39%
Perf 5Y-98.64%
Perf 10Y-
Recom1.00
Target Price3.00
Prev Close0.93
Price0.94
Change %1.02%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
May 19, 2026DowngradeTThe Benchmark CompanyBuy → Speculative Buy$3+220.0%

Peers

Mkt cap
TickerCompanyMkt cap
DERMJourney Medical Corp125.31M
SRTSSensus Healthcare Inc56.13M
BHCBausch Health Companies Inc3.13B
VRCAVerrica Pharmaceuticals Inc67.17M
PTHSPelthos Therapeutics Inc36.92M
ARQTArcutis Biotherapeutics Inc3.59B
SLGLSol-Gel Technologies Ltd207.57M
DRMADermata Therapeutics Inc3.54M
ANIKAnika Therapeutics Inc186.86M
INMDInmode Ltd790.08M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-13--0.110--8.501
2026Q22026-08-13-0.050-0.105-0.05012.009.502
2026Q12026-05-14-0.410-0.115-0.40710.0810.252
2025Q42026-03-190.4800.1950.48417.1016.152
2025Q32025-11-12-0.620-0.580-0.6176.997.002
2025Q22025-08-13-0.570-0.420-0.5699.038.302
2025Q12025-05-15-0.470-0.215-0.4748.5910.552
2024Q42025-03-21-0.190-0.025-0.15712.5614.552
2024Q32024-11-13-0.980-0.835-0.9829.0110.002
2024Q22024-08-14-0.050-0.770-0.0517.848.212
2024Q12024-05-15-2.880-1.170-2.8807.9110.862
2023Q42024-03-154.450-1.1901.64710.5911.522
2023Q32023-11-10-4.640-3.785-4.6408.908.432
2023Q22023-08-11-7.230-43.370-7.2295.856.202
2023Q12023-05-12-0.280-0.195-5.6028.739.152
2022Q42023-03-08-0.105-0.110-2.08610.1410.352

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-85.600-55.900-44.09724.1024.15
2022FY-0.600-0.900-0.60528.6728.85
2023FY-13.020-16.775-13.01934.0735.01
2024FY-3.220-3.035-3.21937.3239.30
2025FY-1.040-1.390-1.04041.7140.75
2026FY--0.180--46.40
2027FY-0.430--53.30
2028FY-0.190--68.36
2029FY-0.310--86.40
2030FY-0.580--109.18

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-061008.508.508.50
2026Q3S2026-10-272008.258.008.50
2026Q3S2026-08-132028.258.008.50
2026Q3S2026-08-012009.009.009.00
2026Q3S2026-05-182019.009.009.00
2026Q3S2026-05-142109.509.0010.00
2026Q3S2026-03-192109.509.0010.00
2026Q3S2026-03-092008.708.409.00
2026Q3S2026-01-271008.408.408.40
2026Q3S2025-11-131018.408.408.40
2026Q3S2025-11-111009.409.409.40
2026Q3S2025-11-101009.409.409.40
2026Q3S2025-11-091009.409.409.40
2026Q3S2025-11-081009.409.409.40

Estimate history

EPS, annual-18.092-18.943-44.097-0.605-13.019-3.219-1.036-0.5863
Period2019202020212022202320242025TTM
EPS, quarterly-0.051-0.982-0.157-0.474-0.569-0.6170.484-0.407-0.047
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual26.18118.84924.128.67434.07137.32141.70546.17
Period2019202020212022202320242025TTM
Sales, quarterly7.8399.01212.5598.5889.036.98817.110.08412.003
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6070.580.8551.3351.5188.87411.64814.206
Period2019202020212022202320242025MRQ
Shares, quarterly5.0946.538.8748.87410.13911.64811.64811.87314.206
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue46.1741.7037.3234.0728.6724.1018.8526.18
Cost of Goods Sold Incl. D&A4.868.9019.0318.5116.3613.289.6313.07
Gross Profit41.3132.8018.2915.5612.3210.829.2213.11
Selling, General and Administrative Excl. Other42.6841.8535.5036.9134.7036.6717.5528.03
Research and Development2.973.722.000.08----
Other Operating Expense0.000.100.000.000.000.000.000.00
Operating Income-1.37-9.15-17.21-21.35-22.38-25.85-8.33-14.92
Interest Expense0.480.452.150.600.370.362.872.13
Unusual Expense5.171.30-1.52-1.78-21.9312.151.274.49
Net Income Before Taxes-6.34-10.51-17.74-20.12-0.61-37.66-10.92-10.95
Income Taxes0.030.030.020.010.030.060.060.03
Consolidated Net Income-6.37-10.54-17.76-20.13-0.64-37.71-10.99-10.98
Net Income From Continuing Operations-6.37-10.54-17.76-20.13-0.64-37.71-10.99-10.98
Net Income-6.37-10.54-17.76-20.13-0.64-37.71-10.99-10.98
EPS (Recurring)-0.21-0.95-3.41-13.82-15.13-34.15-17.41-12.91
EPS (Basic, Before Extraordinaries)-0.59-1.04-3.22-13.02-0.61-44.10-18.94-18.09
EPS (Diluted)-0.59-1.04-3.22-13.02-0.61-44.10-18.94-18.09
EBITDA-0.56-8.28-16.06-20.29-21.21-25.31-7.77-14.26
Non-Operating Income (Expense)0.690.390.100.060.210.701.5510.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.960.750.810.831.460.02--
Price To Sales Ratio0.260.140.160.130.685.34--
Gross Margin89.4778.6549.0245.6842.9644.8948.9250.06
Operating Margin-2.97-21.94-46.11-62.67-78.05-107.27-44.21-57.00
Net Margin-13.78-25.26-47.58-59.09-2.23-156.49-58.29-41.95
Shares Outstanding14.2111.658.871.521.330.860.580.61
Market Capitalization13.7813.788.453.7921.59128.6387.46-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue12.0010.0817.106.999.038.5912.569.01
Cost of Goods Sold Incl. D&A1.010.920.872.072.673.305.314.99
Gross Profit10.999.1716.234.926.365.297.254.03
Selling, General and Administrative Excl. Other10.1211.909.4711.2011.449.848.968.99
Research and Development0.450.900.790.840.851.180.750.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.88-2.736.76-6.28-5.08-4.55-1.71-4.96
Interest Expense0.130.120.120.110.120.120.060.01
Unusual Expense1.361.811.720.28-0.15-0.55-0.350.68
Net Income Before Taxes-0.58-4.755.64-6.64-5.30-4.20-1.40-5.67
Income Taxes0.020.000.000.010.02-0.00-0.000.00
Consolidated Net Income-0.60-4.755.64-6.65-5.32-4.20-1.40-5.67
Net Income From Continuing Operations-0.60-4.755.64-6.65-5.32-4.20-1.40-5.67
Net Income-0.60-4.755.64-6.65-5.32-4.20-1.40-5.67
EPS (Recurring)0.03-0.300.59-0.60-0.58-0.52-0.18-0.90
EPS (Basic, Before Extraordinaries)-0.05-0.410.48-0.62-0.57-0.47-0.16-0.98
EPS (Diluted)-0.05-0.410.48-0.62-0.57-0.47-0.16-0.98
EBITDA1.07-2.546.98-6.07-4.86-4.33-1.49-4.65
Non-Operating Income (Expense)0.03-0.090.720.03-0.26-0.090.02-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.210.340.230.190.150.190.240.23
Price To Sales Ratio0.260.220.160.290.170.190.260.22
Gross Margin91.5990.9294.9170.4470.4561.6157.7544.67
Operating Margin7.30-27.0539.52-89.84-56.25-52.95-13.63-55.04
Net Margin-5.03-47.1232.98-95.15-58.96-48.94-11.12-62.91
Shares Outstanding14.2111.8711.6511.6510.148.878.876.53
Market Capitalization13.789.426.6410.516.727.108.457.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments6.405.911.4227.7624.558.087.30
Short Term Receivables8.515.325.167.4112.433.294.79
Inventories1.436.6510.917.174.467.0910.48
Other Current Assets1.752.835.580.814.991.120.90
Total Current Assets18.0820.7023.0743.1446.4219.5823.47
Net Property, Plant & Equipment3.740.981.751.580.270.370.50
Total Investments and Advances0.200.200.200.000.000.000.00
Long-Term Note Receivable--0.002.812.81--
Intangible Assets2.650.042.633.033.453.874.29
Other Assets3.890.180.280.320.270.320.49
Total Assets28.5622.1027.9350.8853.2224.1428.75
Short Term Debt Incl. Current Port. of LT Debt0.330.554.590.500.000.000.00
Accounts Payable6.677.209.012.590.941.717.81
Other Current Liabilities4.904.274.4917.8112.902.713.93
Total Current Liabilities11.8912.0218.0920.8913.844.4211.74
Long Term Debt5.834.370.800.850.000.0038.20
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.361.274.255.2628.0513.898.99
Total Liabilities18.0817.6723.1427.0141.8818.3158.93
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity10.484.434.7923.8811.345.83-30.18
Total Shareholders Equity10.484.434.7923.8811.345.83-30.18
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity10.484.434.7923.8811.345.83-30.18
Total Liabilities & Stockholders Equity28.5622.1027.9350.8853.2224.1428.75
Book Value Per Share0.900.503.1617.8913.2610.05-49.72
Tangible Book Value Per Share0.670.501.4315.629.223.38-56.78
Full-Time Employees929385816956-
Price to Book Ratio2.211.293.650.9611.34-5.03-
Return on Assets-41.59-70.99-51.08-1.23-97.50-41.55-
Return on Equity-141.30-384.98-140.43-3.63-439.39--
Return on Invested Capital-64.60-201.65-359.67-2.59-332.62-188.52-136.92
Quick Ratio1.401.170.671.723.032.821.11
Current Ratio1.521.721.282.063.364.432.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-6.37-10.54-17.76-20.13-0.64-37.71-10.99-10.98
Depreciation0.810.871.151.061.170.540.560.67
Other Funds (Non Cash)0.97-0.210.13-1.43-19.5211.960.88-3.42
Funds from Operations-4.58-9.88-16.48-20.50-18.99-25.21-9.54-13.74
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-3.34-3.486.21-4.392.79-1.50-2.83-23.94
Cash from Operating Activities-7.93-13.36-10.27-24.89-16.20-26.71-12.37-37.68
Capital Expenditures-0.00-0.00-0.06-0.01-0.04-0.010.00-0.54
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses3.003.000.000.000.000.000.0025.93
Purchase or Sale of Investments0.000.000.060.62-5.120.000.000.00
Purchase of Investments0.000.000.000.00-5.120.000.000.00
Sale Or Maturity of Investments0.000.000.060.620.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities3.003.00-0.000.62-5.16-0.010.0025.39
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.0015.104.5114.0243.190.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.0015.104.5114.0243.190.000.00
Proceedsfrom Stock Options0.000.007.444.519.3929.940.000.00
Issuance or Reduction of Debt, Net10.8510.85-0.273.900.000.008.7913.50
Change in Long Term Debt0.000.004.050.000.000.008.7913.50
Issuance of Long Term Debt0.000.004.050.000.000.008.7913.50
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-8.500.000.000.000.000.004.402.90
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities2.3510.8514.848.4114.0243.1913.1916.40
Net Change in Cash-2.580.494.56-15.87-7.3316.460.824.12
Free Cash Flow-7.93-13.36-10.28-24.90-16.24-26.73-12.37-38.22
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.676.336.403.437.251.79
Short Term Receivables5.543.888.513.003.964.03
Inventories1.101.231.434.334.036.53
Other Current Assets1.131.721.753.663.582.98
Total Current Assets12.4413.1618.0814.4118.8215.33
Net Property, Plant & Equipment4.955.073.740.510.770.77
Total Investments and Advances0.200.200.200.200.200.20
Intangible Assets2.572.612.650.020.030.03
Other Assets3.913.753.890.270.340.25
Total Assets24.0624.7928.5615.4120.1416.59
Short Term Debt Incl. Current Port. of LT Debt0.470.510.330.310.440.43
Accounts Payable5.364.956.675.694.945.95
Other Current Liabilities4.715.474.906.5514.314.58
Total Current Liabilities10.5410.9211.8912.5519.6910.96
Long Term Debt7.037.225.834.604.564.44
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.540.580.360.840.560.72
Total Liabilities18.1118.7218.0818.0024.8116.12
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.966.0710.48-2.58-4.670.47
Total Shareholders Equity5.966.0710.48-2.58-4.670.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.966.0710.48-2.58-4.670.47
Total Liabilities & Stockholders Equity24.0624.7928.5615.4120.1416.59
Book Value Per Share0.420.510.90-0.22-0.460.05
Tangible Book Value Per Share0.240.290.67-0.22-0.460.05
Full-Time Employees--92---
Price to Book Ratio2.210.90-2.57-2.1413.461.60
Return on Assets-28.80-53.58-41.59-103.57-79.55-56.00
Return on Equity-988.35-339.04-141.30-1,191.73-531.54-
Return on Invested Capital-4.65-35.7634.58-329.65--85.67
Quick Ratio1.081.091.400.800.750.80
Current Ratio1.181.201.521.150.961.40

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.60-4.755.64-6.65-5.32-4.20
Depreciation0.200.190.220.210.220.22
Other Funds (Non Cash)0.390.69-0.780.660.14-0.24
Funds from Operations-0.01-3.875.08-5.78-4.96-4.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.643.80-7.461.961.920.10
Cash from Operating Activities-1.66-0.07-2.38-3.82-3.04-4.12
Capital Expenditures0.00-0.010.000.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.003.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.013.000.00-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.00-8.508.500.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.00-8.508.500.000.00
Proceedsfrom Stock Options0.000.00-8.508.500.000.00
Issuance or Reduction of Debt, Net0.000.0010.850.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-8.508.500.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.002.350.008.500.00
Net Change in Cash-1.66-0.072.98-3.825.45-4.12
Free Cash Flow-1.66-0.07-2.38-3.82-3.05-4.12

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 37.32M 2025: 41.71M
United States2024: 37.32M 2025: 41.71M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.48%0.2M12.8M506.32K
2026-10-150.80%0.1M12.8M541.28K
2026-09-301.14%0.1M12.8M561.63K
2026-09-153.62%0.5M12.8M550.35K
2026-08-312.04%0.3M12.5M413.61K
2026-08-140.26%0.0M12.5M340.84K
2026-07-310.57%0.1M10.8M308.98K
2026-07-150.22%0.0M10.9M267.64K
2026-06-300.26%0.0M10.9M215.66K
2026-06-150.51%0.1M10.9M185.40K
2026-05-290.65%0.1M10.7M168.94K
2026-05-150.79%0.1M10.7M179.80K
2026-04-300.78%0.1M9.7M374.14K
2026-04-150.75%0.1M9.7M374.05K
2026-03-312.97%0.3M10.0M475.11K
2026-03-131.75%0.2M10.0M469.45K
2026-02-271.52%0.2M10.0M465.87K
2026-02-134.39%0.4M10.0M451.80K
2026-01-301.42%0.1M10.0M240.13K
2026-01-152.53%0.3M10.0M238.07K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-3025-NSESEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-12SCHEDULE 13G/ASEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-22S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-2210-K/A2025-12-31SEC
2026-06-178-KCurrent report2026-06-11SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-198-KCurrent report2026-03-19SEC
2026-03-098-KCurrent report2026-03-09SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-03-064Statement of changes in beneficial ownership of securities2026-03-04SEC
2026-02-268-KCurrent report2026-02-23SEC
2026-02-11SCHEDULE 13G/ASEC
2026-02-098-KCurrent report2026-02-09SEC
2026-01-28SCHEDULE 13G/ASEC
2026-01-138-KCurrent report2026-01-13SEC
2026-01-078-KCurrent report2025-12-31SEC
2025-12-19EFFECTEffectiveness filing by commission orderSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AIGH Capital Management LLC10.08%
Rosalind Advisors, Inc.9.96%
RENAISSANCE TECHNOLOGIES LLC1.23%
ACADIAN ASSET MANAGEMENT LLC1.11%
CITADEL ADVISORS LLC0.82%
GEODE CAPITAL MANAGEMENT, LLC0.74%
JANE STREET GROUP, LLC0.73%
VANGUARD CAPITAL MANAGEMENT LLC0.56%
VANGUARD FIDUCIARY TRUST CO0.48%
XTX Topco Ltd0.41%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.56%
Fidelity Extended Market Index Fund0.45%
Fidelity Series Total Market Index Fund0.05%
Fidelity Total Market Index Fund0.00%

OakChart. BFRI. Cached 15 minutes.

Some panels did not load: insider.